SymbolsTNFRSF8 ; CD30; D1S166E; Ki-1
External IDsOMIM153243 MGI99908 HomoloGene949 IUPHAR: 1877 GeneCards: TNFRSF8 Gene
RNA expression pattern
File:PBB GE TNFRSF8 206729 at tn.png
More reference expression data
RefSeq (mRNA)NM_001243NM_009401
RefSeq (protein)NP_001234NP_033427
Location (UCSC)Chr 1:
12.12 – 12.2 Mb
Chr 4:
145.27 – 145.32 Mb
PubMed search[1][2]

CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker.


This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. It is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.[1]

Clinical significance

CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus a useful marker in distinguishing between these germ cell tumors.[2] CD30 and CD15 are also expressed on classical Hodgkin Lymphoma Reed-Sternberg cells.[3]

Cancer treatment

CD30 is the target of the FDA approved therapeutic Brentuximab Vedotin (Adcetris), designed and developed by Seattle Genetics. It is approved for use in:

  1. Hodgkin lymphoma (HL) (brentuximab vedotin) after failure of autologous stem cell transplant (ASCT)
  2. HL in patients who are not ASCT candidates after failure of at least 2 multiagent chemotherapy regimens
  3. Systemic anaplastic large cell lymphoma (sALCL) after failure of at least 1 multiagent chemotherapy regimen[4]


CD30 has been shown to interact with TRAF5,[5] TRAF1,[6] TRAF2[5][6] and TRAF3.[6]


  1. ^ "Entrez Gene: TNFRSF8 tumor necrosis factor receptor superfamily, member 8". 
  2. ^ Teng LH, Lu DH, Xu QZ, Fu YJ, Yang H, He ZL (Nov 2005). "[Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors]". Zhonghua Bing Li Xue Za Zhi Chinese Journal of Pathology (in Chinese) 34 (11): 711–5. PMID 16536313. 
  3. ^ Gorczyca W, Tsang P, Liu Z, Wu CD, Dong HY, Goldstein M et al. (Feb 2003). "CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis". International Journal of Oncology 22 (2): 319–24. PMID 12527929. doi:10.3892/ijo.22.2.319. 
  4. ^ Deng C, Pan B, O'Connor OA (Jan 2013). "Brentuximab vedotin". Clinical Cancer Research 19 (1): 22–7. PMID 23155186. doi:10.1158/1078-0432.CCR-12-0290. 
  5. ^ a b Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K et al. (Jan 1997). "Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation". The Journal of Biological Chemistry 272 (4): 2042–5. PMID 8999898. doi:10.1074/jbc.272.4.2042. 
  6. ^ a b c Ansieau S, Scheffrahn I, Mosialos G, Brand H, Duyster J, Kaye K et al. (Nov 1996). "Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation". Proceedings of the National Academy of Sciences of the United States of America 93 (24): 14053–8. PMC 19493. PMID 8943059. doi:10.1073/pnas.93.24.14053.  (Retracted. If this is intentional, please replace {{Retracted}} with {{Retracted|intentional=yes}}.)

Further reading


External links

This article incorporates text from the United States National Library of Medicine, which is in the public domain.